Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | TUB-030 |
| Synonyms | |
| Therapy Description |
TUB-030 is an antibody-drug conjugate (ADC) comprising an antibody targeting TPBG (5T4) linked to the topoisomerase I inhibitor exatecan, which potentially induces cytotoxicity against TPBG (5T4)-expressing tumor cells and inhibits tumor growth (Cancer Res (2024) 84 (6_Supplement): 2623). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| TUB-030 | TUB030|TUB 030 | TUB-030 is an antibody-drug conjugate (ADC) comprising an antibody targeting TPBG (5T4) linked to the topoisomerase I inhibitor exatecan, which potentially induces cytotoxicity against TPBG (5T4)-expressing tumor cells and inhibits tumor growth (Cancer Res (2024) 84 (6_Supplement): 2623). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06657222 | Phase Ib/II | TUB-030 | First in Human Study of TUB-030 in Patients With Advanced Solid Tumors | Recruiting | USA | CAN | 0 |